181 related articles for article (PubMed ID: 32571298)
1. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
2. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
3. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
4. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
5. How to design a dose-finding study using the continual reassessment method.
Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
[TBL] [Abstract][Full Text] [Related]
6. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
Yin Z; Mander AP; de Bono JS; Zheng H; Yap C
JCO Precis Oncol; 2024 Jan; 8():e2300441. PubMed ID: 38181316
[TBL] [Abstract][Full Text] [Related]
7. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
8. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Andrillon A; Biard L; Lee SM
J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
[TBL] [Abstract][Full Text] [Related]
9. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
10. Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.
Yin G; Yang Z
Contemp Clin Trials Commun; 2020 Sep; 19():100650. PubMed ID: 32875142
[TBL] [Abstract][Full Text] [Related]
11. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding design and benchmark for a right censored endpoint.
Andrillon A; Chevret S; Lee SM; Biard L
J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
[TBL] [Abstract][Full Text] [Related]
13. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
14. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
Chapple AG; Thall PF
Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a two-group likelihood time-to-event continual reassessment method using SAS.
Salter A; Morgan C; Aban IB
Comput Methods Programs Biomed; 2015 Oct; 121(3):189-96. PubMed ID: 26122068
[TBL] [Abstract][Full Text] [Related]
16. Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
Patel A; Brock K; Slade D; Gaunt C; Kong A; Mehanna H; Billingham L; Gaunt P
BMC Med Res Methodol; 2024 Jan; 24(1):11. PubMed ID: 38218799
[TBL] [Abstract][Full Text] [Related]
17. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
Zhao L; Lee J; Mody R; Braun TM
Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
[TBL] [Abstract][Full Text] [Related]
18. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities.
Braun TM
Stat Med; 2006 Jun; 25(12):2071-83. PubMed ID: 16217853
[TBL] [Abstract][Full Text] [Related]
19. Sequential designs for phase I clinical trials with late-onset toxicities.
Cheung YK; Chappell R
Biometrics; 2000 Dec; 56(4):1177-82. PubMed ID: 11129476
[TBL] [Abstract][Full Text] [Related]
20. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
